A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

February 9, 2023

Study Completion Date

February 9, 2023

Conditions

Psoriasis

Interventions

DRUG

SAR441566

Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions

DRUG

Placebo

Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition

Trial Locations (1)

Investigational Site Number :2760001, Berlin